2019 IPO

Alector Stock

Therapeutics for neurodegenerative disorders

Sign up today and learn more about Alector Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Alector Stock

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

Funding History

October 2013$0
March 2014$0
September 2015$32.0M
January 2016$29.5M
July 2018$133M


Founder, President & Chief Executive Officer

Arnon Rosenthal

Founder & Chairman of the Board

Tillman Gerngross

Founder & SAB Member

Asa Abeliovich

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: